
    
      The investigators will undertake a 6-week, double-blind, randomized, parallel-group,
      placebo-controlled trial of adjunctive asenapine in 130 patients with MDD without psychosis
      who have had an incomplete therapeutic response to treatment with an antidepressant
      medication alone.
    
  